Post by
Trogarzon on Mar 08, 2023 5:10pm
Dressing up the bride
Could some of the latest developments be interpreted as some kind of preparation for a sale. They now own the rights to Egrifta and taken the steps to improve drug delevery on both drugs. They cleaned up the balance sheet with Marathon. Now a buyer could also refinance the dept at much better conditions probably and increase the potential return on their investment. Maybe the downbeat tone is meant to get shareholders to accept a deal that could not occur otherwise. I saw this occur in other instances involving private companies tought.
Comment by
SPCEO1 on Mar 08, 2023 5:13pm
No, I don't think any of that is likely.
Comment by
Trogarzon on Mar 08, 2023 5:17pm
Ok I get it that Pharma companies don't operate that way. They will pay billions for later stage stuff and won't bother with this thing, fine, but what about specialised player that just look at the legacy stuff and try to capitalise on it.